Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Plans Parallel HTA And Marketing Authorization Reviews

Executive Summary

Canada plans to run regulatory reviews and health technology appraisals in parallel for certain new medicines. This could mean some companies get their drugs listed on public health plans almost immediately upon market authorization, rather than having to wait for more than a year.

You may also be interested in...



Canada To Speed Market Access With Aligned HTA And Marketing Authorization Reviews

Drug sponsors can opt into the newly launched Canadian parallel review scheme at any stage of the marketing authorization review process, but the earlier they do so the better.

Canada Plans Drug Price Reductions By Changing Reference Country List

Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.

Italy To Consult On Pricing Transparency Requirements

Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel